$OM
Outset Medical, Inc.

2023 Q3 Form 10-Q Financial Statement

#000095017023037387 Filed on August 03, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $30.36M $36.04M
YoY Change 9.37% 43.83%
Cost Of Revenue $23.21M $28.34M
YoY Change -0.94% 33.19%
Gross Profit $7.157M $7.703M
YoY Change 65.06% 103.68%
Gross Profit Margin 23.57% 21.37%
Selling, General & Admin $36.54M $36.28M
YoY Change 13.2% 6.75%
% of Gross Profit 510.48% 470.92%
Research & Development $16.08M $14.91M
YoY Change 23.1% 10.24%
% of Gross Profit 224.62% 193.51%
Depreciation & Amortization $1.460M $1.514M
YoY Change 11.11% 14.35%
% of Gross Profit 20.4% 19.65%
Operating Expenses $52.61M $51.18M
YoY Change 16.05% 7.74%
Operating Profit -$45.45M -$43.48M
YoY Change 10.87% -0.56%
Interest Expense $3.213M $3.103M
YoY Change 466.67% 545.11%
% of Operating Profit
Other Income/Expense, Net $2.573M $2.668M
YoY Change 219.63% 481.26%
Pretax Income -$46.09M -$43.91M
YoY Change 13.08% 0.39%
Income Tax $86.00K $133.0K
% Of Pretax Income
Net Earnings -$46.18M -$44.05M
YoY Change 13.24% 0.47%
Net Earnings / Revenue -152.1% -122.21%
Basic Earnings Per Share -$0.93 -$0.90
Diluted Earnings Per Share -$0.93 -$0.90
COMMON SHARES
Basic Shares Outstanding 49.79M 49.23M
Diluted Shares Outstanding 49.91K 48.95K

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $128.9M $175.2M
YoY Change -43.33% -33.14%
Cash & Equivalents $36.30M $36.39M
Short-Term Investments $92.65M $138.8M
Other Short-Term Assets $6.000M $5.216M
YoY Change 27.28% -3.39%
Inventory $48.26M $44.50M
Prepaid Expenses
Receivables $35.49M $36.90M
Other Receivables $0.00 $0.00
Total Short-Term Assets $283.8M $309.4M
YoY Change -8.46% -10.52%
LONG-TERM ASSETS
Property, Plant & Equipment $13.77M $14.54M
YoY Change -11.8% -4.63%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $961.0K $1.128M
YoY Change 148.96% 422.22%
Total Long-Term Assets $23.78M $25.04M
YoY Change -57.33% -54.85%
TOTAL ASSETS
Total Short-Term Assets $283.8M $309.4M
Total Long-Term Assets $23.78M $25.04M
Total Assets $307.6M $334.4M
YoY Change -15.91% -16.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.880M $2.217M
YoY Change 99.45% -19.47%
Accrued Expenses $34.70M $30.85M
YoY Change 1.94% -16.57%
Deferred Revenue $10.83M $10.85M
YoY Change 38.38% 40.02%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $53.02M $48.82M
YoY Change 6.81% -11.61%
LONG-TERM LIABILITIES
Long-Term Debt $96.78M $96.63M
YoY Change 224.47% 235.45%
Other Long-Term Liabilities $5.700M $5.881M
YoY Change -20.25% -20.81%
Total Long-Term Liabilities $96.78M $96.63M
YoY Change 224.47% 235.45%
TOTAL LIABILITIES
Total Short-Term Liabilities $53.02M $48.82M
Total Long-Term Liabilities $96.78M $96.63M
Total Liabilities $155.5M $151.3M
YoY Change 79.51% 65.44%
SHAREHOLDERS EQUITY
Retained Earnings -$923.1M -$877.0M
YoY Change 23.49% 24.1%
Common Stock $1.075B $1.060B
YoY Change 4.66% 4.23%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $152.1M $183.1M
YoY Change
Total Liabilities & Shareholders Equity $307.6M $334.4M
YoY Change -15.91% -16.65%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$46.18M -$44.05M
YoY Change 13.24% 0.47%
Depreciation, Depletion And Amortization $1.460M $1.514M
YoY Change 11.11% 14.35%
Cash From Operating Activities -$34.00M -$28.18M
YoY Change -0.91% -26.96%
INVESTING ACTIVITIES
Capital Expenditures $780.0K $795.0K
YoY Change -128.46% -139.81%
Acquisitions
YoY Change
Other Investing Activities $30.59M $27.95M
YoY Change 33.58% 4003.96%
Cash From Investing Activities $29.80M $27.15M
YoY Change 47.82% -2163.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.100M 1.043M
YoY Change 61.86% 0.1%
NET CHANGE
Cash From Operating Activities -34.00M -28.18M
Cash From Investing Activities 29.80M 27.15M
Cash From Financing Activities 4.100M 1.043M
Net Change In Cash -100.0K 20.00K
YoY Change -99.14% -100.05%
FREE CASH FLOW
Cash From Operating Activities -$34.00M -$28.18M
Capital Expenditures $780.0K $795.0K
Free Cash Flow -$34.78M -$28.97M
YoY Change 10.16% -20.8%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001484612
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
CY2023Q2 om Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
12650000
CY2022Q4 om Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
16227000
CY2023Q2 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
4168000
CY2022Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
3620000
CY2023Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
10854000
dei Entity File Number
EntityFileNumber
001-39513
dei Entity Registrant Name
EntityRegistrantName
Outset Medical, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-0514392
dei Entity Address Address Line1
EntityAddressAddressLine1
3052 Orchard Dr.
dei Entity Address City Or Town
EntityAddressCityOrTown
San Jose
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
95134
dei City Area Code
CityAreaCode
669
dei Local Phone Number
LocalPhoneNumber
231-8200
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
OM
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
49790212
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36388000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
73222000
CY2023Q2 us-gaap Short Term Investments
ShortTermInvestments
186403000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
214280000
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
36902000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
28070000
CY2023Q2 us-gaap Inventory Net
InventoryNet
44495000
CY2022Q4 us-gaap Inventory Net
InventoryNet
51476000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5216000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6597000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
309404000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
373645000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3329000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3311000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14539000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15876000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6042000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6117000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1128000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1166000
CY2023Q2 us-gaap Assets
Assets
334442000
CY2022Q4 us-gaap Assets
Assets
400115000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2217000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
603000
CY2023Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
17461000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
21519000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
8662000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1474000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1318000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
48824000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
51949000
CY2023Q2 om Accrued Interest Noncurrent
AccruedInterestNoncurrent
484000
CY2022Q4 om Accrued Interest Noncurrent
AccruedInterestNoncurrent
113000
CY2023Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
89000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
151000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5308000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5576000
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
96629000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
96336000
CY2023Q2 us-gaap Liabilities
Liabilities
151334000
CY2022Q4 us-gaap Liabilities
Liabilities
154125000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49629000
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49629000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48465000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48465000
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
50000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
48000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1060418000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1035456000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-393000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-564000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-876967000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-788950000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
183108000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
245990000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
334442000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
400115000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
36040000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25057000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
69507000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
55607000
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
28337000
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
21275000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
55376000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
47383000
CY2023Q2 us-gaap Gross Profit
GrossProfit
7703000
CY2022Q2 us-gaap Gross Profit
GrossProfit
3782000
us-gaap Gross Profit
GrossProfit
14131000
us-gaap Gross Profit
GrossProfit
8224000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14906000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13521000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28699000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24352000
CY2023Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
24985000
CY2022Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
23198000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
49318000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
43575000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11290000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10784000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23077000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20493000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
51181000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
47503000
us-gaap Operating Expenses
OperatingExpenses
101094000
us-gaap Operating Expenses
OperatingExpenses
88420000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-43478000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-43721000
us-gaap Operating Income Loss
OperatingIncomeLoss
-86963000
us-gaap Operating Income Loss
OperatingIncomeLoss
-80196000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2668000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
459000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5316000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
579000
CY2023Q2 us-gaap Interest Expense
InterestExpense
3103000
CY2022Q2 us-gaap Interest Expense
InterestExpense
481000
us-gaap Interest Expense
InterestExpense
6045000
us-gaap Interest Expense
InterestExpense
903000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-43913000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-43743000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-87692000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-80520000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
133000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
96000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
325000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
211000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-44046000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-43839000
us-gaap Net Income Loss
NetIncomeLoss
-88017000
us-gaap Net Income Loss
NetIncomeLoss
-80731000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.9
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.9
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.92
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.92
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.79
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.79
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.69
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.69
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48951
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48951
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47882
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47882
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49085
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49085
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47686
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47686
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-44046000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-43839000
us-gaap Net Income Loss
NetIncomeLoss
-88017000
us-gaap Net Income Loss
NetIncomeLoss
-80731000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-280000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-306000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
171000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-771000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-44326000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-44145000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-87846000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-81502000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
245990000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
4594000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
684000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8538000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
451000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-43971000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
216286000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1043000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10105000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-280000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-44046000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
183108000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
374081000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2063000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1660000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
133015000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
129250000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
101784000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
29796000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-34706000
om Proceeds From Stock Options Exercised And Employee Stock Purchase Plan Purchases
ProceedsFromStockOptionsExercisedAndEmployeeStockPurchasePlanPurchases
6320000
om Proceeds From Stock Options Exercised And Employee Stock Purchase Plan Purchases
ProceedsFromStockOptionsExercisedAndEmployeeStockPurchasePlanPurchases
4765000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6320000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4765000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-36816000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5006000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-465000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-36892000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
345453000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1042000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7414000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-306000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-43839000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
309764000
us-gaap Net Income Loss
NetIncomeLoss
-88017000
us-gaap Net Income Loss
NetIncomeLoss
-80731000
us-gaap Share Based Compensation
ShareBasedCompensation
18643000
us-gaap Share Based Compensation
ShareBasedCompensation
12420000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2898000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2586000
om Non Cash Lease Expense
NonCashLeaseExpense
603000
om Non Cash Lease Expense
NonCashLeaseExpense
544000
om Non Cash Interest Expense
NonCashInterestExpense
914000
om Non Cash Interest Expense
NonCashInterestExpense
282000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3353000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1035000
om Provision For Inventories
ProvisionForInventories
868000
om Provision For Inventories
ProvisionForInventories
808000
om Other Non Cash Items
OtherNonCashItems
180000
om Other Non Cash Items
OtherNonCashItems
29000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
8919000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-964000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-6114000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
15311000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-1196000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-70000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1682000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
684000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-4058000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-9153000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-3720000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
8366000
om Increase Decrease In Accrued Warranty Liability
IncreaseDecreaseInAccruedWarrantyLiability
547000
om Increase Decrease In Accrued Warranty Liability
IncreaseDecreaseInAccruedWarrantyLiability
-260000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2130000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1305000
om Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-640000
om Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-548000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-72932000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-76910000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1605000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3475000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
97849000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-106851000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
76533000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
215659000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
39717000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
108808000
us-gaap Income Taxes Paid
IncomeTaxesPaid
311000
us-gaap Income Taxes Paid
IncomeTaxesPaid
283000
us-gaap Interest Paid Net
InterestPaidNet
5131000
us-gaap Interest Paid Net
InterestPaidNet
621000
om Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities
640000
om Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities
548000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
216000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1613000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
528000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Net Income Loss
NetIncomeLoss
-88000000
us-gaap Net Income Loss
NetIncomeLoss
-80700000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-877000000
CY2023Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
222800000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3300000
CY2023Q2 om Cash Cash Equivalents Restricted Cash And Short Term Investments
CashCashEquivalentsRestrictedCashAndShortTermInvestments
226100000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
36040000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25057000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
69507000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
55607000
CY2023Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
11000000
CY2023Q2 om Revenue Performance Obligation1
RevenuePerformanceObligation1
10900000
CY2023Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P12M
CY2023Q2 om Revenue Performance Obligation1
RevenuePerformanceObligation1
100000
CY2023Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
2400000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
6200000
om Debt Securities Available For Sale Remaining Contractual Maturities Period
DebtSecuritiesAvailableForSaleRemainingContractualMaturitiesPeriod
one month to fourteen months
CY2023Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
138816000
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
404000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
154534000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
615000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
3300000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
3300000
om Cash Cash Equivalents And Restricted Cash
CashCashEquivalentsAndRestrictedCash
<p style="text-indent:5.067%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table provides a reconciliation of cash, cash equivalents and restricted cash that sum to the total of the amounts shown in the accompanying condensed statements of cash flows (in thousands):</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.08%;"></td> <td style="width:1.622%;"></td> <td style="width:1.0%;"></td> <td style="width:12.837%;"></td> <td style="width:1.0%;"></td> <td style="width:1.622%;"></td> <td style="width:1.0%;"></td> <td style="width:12.837%;"></td> <td style="width:1.0%;"></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 30,</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36,388</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75,497</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,329</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,311</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash, cash equivalents and restricted cash</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39,717</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108,808</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td> </tr> </table>
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36388000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75497000
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
3329000
CY2022Q2 us-gaap Restricted Cash
RestrictedCash
33311000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39717000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
108808000
CY2023Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
20771000
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
20623000
CY2023Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
11062000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
9086000
CY2023Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
12662000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
21767000
CY2023Q2 us-gaap Inventory Net
InventoryNet
44495000
CY2022Q4 us-gaap Inventory Net
InventoryNet
51476000
CY2023Q2 om Accrued Inventory Current
AccruedInventoryCurrent
3404000
CY2022Q4 om Accrued Inventory Current
AccruedInventoryCurrent
5585000
CY2023Q2 om Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
868000
CY2022Q4 om Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
908000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1345000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1261000
CY2023Q2 us-gaap Accrued Exchange Fee Rebate Current
AccruedExchangeFeeRebateCurrent
2126000
CY2022Q4 us-gaap Accrued Exchange Fee Rebate Current
AccruedExchangeFeeRebateCurrent
1364000
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4907000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
7109000
CY2023Q2 om Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
12650000
CY2022Q4 om Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
16227000
CY2023Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
100000000
CY2022Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
100000000
CY2023Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
3371000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
3664000
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
96629000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
96336000
om Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Percentage Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageVestedInPeriod
0.50
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10105000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7414000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18643000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12420000
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5104000
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4608000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5104000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4608000
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-23-037387-index-headers.html Edgar Link pending
0000950170-23-037387-index.html Edgar Link pending
0000950170-23-037387.txt Edgar Link pending
0000950170-23-037387-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
om-20230630.htm Edgar Link pending
om-20230630.xsd Edgar Link pending
om-ex31_1.htm Edgar Link pending
om-ex31_2.htm Edgar Link pending
om-ex32_1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
om-20230630_cal.xml Edgar Link unprocessable
om-20230630_def.xml Edgar Link unprocessable
om-20230630_lab.xml Edgar Link unprocessable
om-20230630_pre.xml Edgar Link unprocessable
om-20230630_htm.xml Edgar Link completed
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending